Imunon (IMNN) Retained Earnings (2010 - 2026)
Imunon's (IMNN) quarterly Retained Earnings came in at -$425.5 million in Q1 2026, down 203.46% YoY from $411.3 million in Q1 2025, and down 1.01% on a QoQ basis from -$421.3 million in Q4 2025.
Imunon (IMNN) Retained Earnings (2010 - 2026) Analysis & Trends
Imunon (IMNN) has 17 years of Retained Earnings data on file, last reported at -$425.5 million in Q1 2026.
- Quarterly Retained Earnings fell 203.46% year-over-year to -$425.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$425.5 million (down 203.46% YoY) and the FY2025 annual result came in at -$421.3 million, down 202.47% from the prior year.
- Retained Earnings retreated to -$425.5 million in Q1 2026, from -$421.3 million in the prior quarter.
- In the past five years, Retained Earnings ranged from a high of $421.2 million in Q3 2025 to a low of -$425.5 million in Q1 2026.
- A 5-year average of $50.9 million and a median of $26494.0 in 2022 frame the typical range for Retained Earnings.
- Annual changes were most pronounced in 2024 — Retained Earnings surged 1972006.68% — and 2026, when it tumbled 203.46%.
- Tracing IMNN's Retained Earnings over 5 years: stood at $26494.0 in 2022, then jumped by 1515340.62% to $401.5 million in 2023, then rose by 2.4% to $411.1 million in 2024, then tumbled by 202.47% to -$421.3 million in 2025, then slipped by 1.01% to -$425.5 million in 2026.
- The last three Retained Earnings figures came in at -$425.5 million (Q1 2026), -$421.3 million (Q4 2025), and $421.2 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 558.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 5.10 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 13.05 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | -6.33 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 6.57 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 4.38 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 20.91 Bn |
| 10 | Imunon | 8.16 Mn | 8.16 Mn | - | 428.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 428.00 Mn |
| Mar 31, 2026 | -425.55 Mn |
| Dec 31, 2025 | -421.30 Mn |
| Sep 30, 2025 | 421.21 Mn |
| Jun 30, 2025 | -413.65 Mn |
| Mar 31, 2025 | 411.30 Mn |
| Dec 31, 2024 | 411.12 Mn |
| Sep 30, 2024 | 403.00 Mn |
| Jun 30, 2024 | 401.63 Mn |
| Mar 31, 2024 | -393.11 Mn |
| Dec 31, 2023 | 401.50 Mn |
| Sep 30, 2023 | 20,435.00 |
| Jun 30, 2023 | -379.82 Mn |
| Mar 31, 2023 | 400.78 Mn |
| Dec 31, 2022 | 26,494.00 |
| Sep 30, 2022 | 396.83 Mn |
| Jun 30, 2022 | -349.29 Mn |
| Mar 31, 2022 | -58,978.00 |
| Dec 31, 2021 | -332.77 Mn |
| Sep 30, 2021 | 387.11 Mn |